Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer

Inclusion Criteria: 1. Age:18-80 2. Diagnosis：advanced and active pancreatic cancer 3. The tumour is measurable 4. Eastern Cooperative Oncology Group(ECOG) score：0\~2；3 but has no relationship with tumour 5. Vital organ function is normal: total bilirubin(TB) \<68μmol/L aspartate aminotransferase(AST)\<90 IU/L Cre\<353μmol/L white blood cell count(WBC)\<9×10\^9/L,when WBC is close to or even greater than 9×10\^9/L，the recommended dose should be halved platelet count(PLT)\>80×10\^9/L Red blood cell specific volume(HCT)\>0.20 Non severe viral or bacterial infection 6. Non pregnant and lactating patients 7. Non allergic reactions to biological products 8. Informed and consent Exclusion Criteria: 1. Patients with cardiac pacemaker 2. Patients with severe cardiac and pulmonary dysfunction 3. Patients that the researchers do not think fit into the group,including patients failed in compliance assessment